Virtu Financial’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Virtu Financial’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-32,791	Closed	-$8K	–	2209
2024 Q4	$8K	Buy	32,791 +13,162	+67%	+$15.8K	﹤0.01%	1410
2024 Q3	$42K	Buy	+19,629	New	+$70.5K	﹤0.01%	1044
2024 Q2	–	Sell	-12,030	Closed	-$64K	–	1999
2024 Q1	$64K	Buy	+12,030	New	+$83.2K	﹤0.01%	985
2023 Q1	–	Sell	-12,428	Closed	-$45K	–	2211
2022 Q4	$45K	Buy	+12,428	New	+$53.9K	0.01%	1102
2022 Q3	–	Sell	-1,183	Closed	-$11K	–	2340
2022 Q2	$11K	Sell	1,183 -69	-6%	-$645	﹤0.01%	1421
2022 Q1	$15K	Buy	+1,252	New	+$22.4K	﹤0.01%	1338
2021 Q4	–	Sell	-2,094	Closed	-$94K	–	2271
2021 Q3	$94K	Buy	+2,094	New	+$102K	0.01%	1161
2021 Q2	–	Sell	-3,399	Closed	-$254K	–	2169
2021 Q1	$254K	Buy	+3,399	New	+$353K	0.02%	914
2018 Q1	–	Sell	-1,966	Closed	-$191K	–	2738
2017 Q4	$191K	Buy	+1,966	New	+$264K	0.01%	1707

Other funds holding SYRS

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BBA

Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

1CM

1492 Capital Management Milwaukee, Wisconsin $339M AUM 120.53% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Virtu Financial's SYRS Position: Q1 2025 in Review

Virtu Financial sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2025, closing a stake of 32,791 shares — an estimated $8K sold.

Virtu Financial first reported a position in SYRS in Q4 2017 and held it in 9 quarters. The position peaked at $254K in Q1 2021. 7 funds tracked by Wall St. Rank hold SYRS as of Q1 2025.

Virtu Financial reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Virtu Financial sold 32,791 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $8K.
Virtu Financial first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 9 quarters.
Virtu Financial's Syros Pharmaceuticals, Inc. Common Stock position peaked at $254K in Q1 2021.
7 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2025.

Based on Virtu Financial's 13F filing for Q1 2025, filed 12 May 2025.